The Microbiota in Inflammatory Bowel Disease
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Gut Microbiota".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 5485
Special Issue Editor
Special Issue Information
Dear Colleagues,
Modulation of the gut microbiota using fecal microbiota transplantation (FMT), diet or pre-, pro-, or antibiotics is attracting increased attention as potential future treatment modalities for a wide range of intestinal dysbiosis-related diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), antibiotic-associated diarrhea, obesity, intestinal cancer, and more. A substantial imbalance has been observed across major bacterial phyla, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, influencing the intestinal microbiomes’ beneficial effects on the host through changes in the production of short-chain fatty acids (SCFA) and amino acids, metabolism of undigested carbohydrate, and stimulation of the immune system. Recent publications have demonstrated positive effects of FMT on disease activity in IBD in randomized placebo-controlled trials. Furthermore, abundance or lack of a single or a few bacterial species such as, e.g., Faecalibacterium Prausnitzii and E. coli pathobionts, could possibly be decisive in disease outcome. Therefore, precision modulation of the intestinal microbiome may be a viable principle for a targeted future treatment of IBD, with few side effects. We welcome original research articles or review articles on all kinds of microbiota manipulation in IBD, focusing on clinical outcomes in vitro, in animal and in human studies.
Dr. Andreas Munk Petersen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Inflammatory bowel disease
- Ulcerative colitis
- Crohn’s disease
- Microbiota
- Probiotics
- Fecal microbiota transplantation
- Antibiotics
- Dysbiosis
